See analyst estimates and all valuation multiples for Genomics & Personalized Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $32.5B | 14.9x | -101.7x | |
| $21.5B | 5.0x | 18.1x | |
| $20.7B | 6.5x | 45.5x | |
| $14.2B | 14.8x | -66.0x | |
| $4.6B | 11.0x | 120.2x | |
| $3.3B | 22.9x | -7.4x | |
| $3.1B | 6.2x | 24.3x | |
| $2.6B | 2.9x | 15.6x | |
| $2.2B | 4.0x | -1310.2x | |
| $1.9B | 2.9x | -26.8x | |
| $1.8B | 4.6x | -43.7x | |
| $1.7B | n/a | n/a | |
| $1.3B | 2.3x | 19.2x | |
| $1.2B | 203.9x | -10.6x | |
| $1.1B | 7.2x | -7.7x | |
| $866M | 2.6x | 22.6x | |
| $824M | 2.2x | 22.2x | |
| $753M | 30.0x | n/a | |
| $752M | 0.9x | 23.9x | |
| $713M | 10.1x | -9.1x | |
| $661M | 119.3x | -3.4x | |
| $591M | 1.9x | 11.0x | |
| $580M | n/a | -5.3x | |
| $481M | 1.5x | -86.2x | |
| $380M | n/a | -3.2x | |
| $378M | 75.7x | n/a | |
| $378M | 5.5x | -6.8x | |
| $357M | n/a | n/a | |
| $294M | 3.9x | -6.8x | |
| $288M | n/a | n/a | |
| $282M | n/a | -54.3x | |
| $234M | n/a | -1.3x | |
| $224M | 5.9x | -1.8x | |
| $215M | 2.3x | n/a | |
| $190M | n/a | -2.1x | |
| $176M | n/a | n/a | |
| $165M | 2.5x | -3.5x | |
| $159M | 428.1x | -0.8x | |
| $147M | 45.0x | -2.7x | |
| $121M | 52.0x | -5.6x | |
| $101M | 8.1x | -1.4x | |
| $101M | 18.5x | n/a | |
| $99.1M | 23.7x | -1.8x | |
| $92.2M | 3.8x | -0.5x | |
| $53.0M | 5.6x | -0.4x | |
| $36.6M | 0.8x | n/a | |
| $20.5M | 3.8x | n/a | |
| $13.3M | n/a | n/a | |
| $12.5M | 0.4x | -0.1x | |
| $10.3M | n/a | n/a | |
| $8.7M | n/a | n/a | |
| $4.6M | n/a | n/a | |
| $0.3M | n/a | -0.0x | |
| -$27.3M | -2.4x | n/a | |
| -$36.1M | -0.3x | n/a | |
| -$75.2M | -2.5x | 0.8x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Genomics & Personalized Medicine